Breaking GLP-1 Industry News In Real Time. Live M/W/F at 12pm Eastern. New podcast every Tuesday.
Joined March 2023
- Tweets4.5K
- Following431
- Followers6.8K
- Likes2.1K
$LLY has a triple agonist ORAL peptide entering phase two clinical trials 👀
Like #retatrutide it’s a GGG. GLP-1/GIP/Glucagon.
Just trying to follow along…
What’s OK:
- Stealing retatrutide formula from Lilly
- Using their clinical trial data to sell it
What’s not OK:
- Stealing a peptide formula from another RUO brand
- Using their information to sell it
Fascinating…
Lepto3GR and the BioLongevity Lookalike Selling It
A separate website uses BioLongevity’s branding to advertise a product whose launch appears to have been shelved.
A website at biolongevitylabspeptides.com… is advertising Lepto3GR for $249.97 per 50 mcg vial, complete with BioLongevity branding, founder names and detailed scientific claims.
It’s not the official biolongevitylabs.com/ domain, and no connection between the two has been verified. Lepto3GR was not found in the official site’s current catalogue. The listing should not be treated as an authentic BioLongevity offer.
The lookalike goes beyond borrowing a logo. It names Jay Campbell and Hunter Williams, displays branded vials and supplies a peptide sequence, molecular formula and 99% purity claim. None of those details authenticates the seller or establishes what’s in a vial.
Lepto3GR itself does have a BioLongevity connection. Campbell promoted it as “Super Retatrutide,” named Mike Farber as its chemist and published claims of stronger GLP-1, GIP and glucagon receptor binding. Some wording on the lookalike therefore resembles genuine promotional material. That makes the website more convincing, not more trustworthy.
Its launch subsequently appears to have been shelved. In a September interview, Campbell described contact involving Lilly and BioLongevity’s attorney, followed by a decision to change direction. He was likely referring to Lepto3GR, which he had previously promoted as “Super Retatrutide.”
The link in my earlier article led to this separate website. Its price, vial size and product specifications should be disregarded.
A familiar logo, real founder names and convincing product copy can all be reproduced. They’re no substitute for checking the address at the top of the page.
A question that needs to be asked:
Could long-term GLP-1 use negatively reshape reward circuitry in some people after years or decades of altered dopamine and reward signaling?
The more we learn about how these medications work in the brain, how do patients ensure that science is asking the right questions about their long-term use?
On The Pen™ retweeted
Unbelievable!
Mass General cutting coverage on essentially ALL obesity medicines!
Not just GLP-1RAs, but also orlistat, phentermine/topiramate, naltrexone/bupropion.
Even Plenity, which isn’t even a drug, but a space-occupying device!
Are we entering a new Dark Age of Obesity Medicine?
youtu.be/TSdccEnaOK8
🚨 BREAKING EXCLUSIVE: GLP-1 ACCESS
Massachusetts General Hospital was ground zero for some of the foundational science that gave us GLP-1 medicines, and later became a founding member of Mass General Brigham.
Now, beginning Jan. 1, affected MGB employee health plans are REMOVING GLP-1 obesity drugs from the traditional pharmacy benefit, while a CVS letter obtained by On The Pen shows other obesity medications are being removed as well.
MGB confirmed the change directly to On The Pen and says eligible employees will instead receive income-tiered financial assistance through an HRA.
The institution that helped teach the world obesity is biology is now at the center of a fight over what access to treatment should look like.
Full story + MGB’s exclusive statement: 👇
onthepen.com/news/exclusive-…
Women Are Losing 25% on CagriSema, Even After Menopause xitter.cf/i/broadcasts/1pJkOXlav…
$HIMS is already cooking up a GLP-1 compound with this med added to it, no doubt. 😂
🚨 Novo just dropped a BIG CagriSema data point:
Women in a Phase 3 analysis lost an average 25% of their body weight at 68 weeks.
By menopausal status:
• Premenopausal: 26.7%
• Perimenopausal: 24.8%
• Postmenopausal: 23.1%
CagriSema combines semaglutide + cagrilintide, hitting GLP-1 and amylin pathways.
Very interesting data given how much hormones can affect weight…
🚨 NEW ON THE PEN PODCAST
A compounded tirzepatide recall. “Floaters” in compounded semaglutide. Hyalo vials with reported visible strands. FDA inspectors finding black mold, insects, hidden paperwork, and questionable testing at GLP-1 ingredient suppliers.
And then, on the other side of the spectrum, CagriSema may be right around the corner and Lilly just made a $1.1B bet on next-generation drug delivery.
This episode is about the whole picture.
What happened, how rare these events appear relative to millions of compounded GLP-1 users, where the transparency gaps are, and why the search for better obesity and diabetes treatments cannot end with weekly shots forever.
youtu.be/koV-depTOpM?is=WI-s…
Eli Lilly watching 503B’s get hit with tirzepatide recalls a year and a half after the shortages ended.
Seeing the peptide folks freak out about TikTok censorship is yet another reminder that this is the only major platform where open and honest dialogue is allowed to exist.
I’ve lost my account multiple times over there for simply educating folks about obesity and the meds that treat it.
🚨 Lilly just made another deal that could quietly matter A LOT for the future of obesity treatment.
$LLY is partnering with METiS TechBio in a deal worth up to $1.1 BILLION to develop AI-designed lipid nanoparticles capable of delivering therapies to specific tissues.
This isn’t an obesity-specific deal. But think bigger than another GLP-1.
If Lilly can eventually use this technology to deliver RNA, gene-editing tools or other therapeutic payloads directly into metabolic tissues, we could be talking about drugs designed to alter obesity biology much closer to the source, potentially with very different dosing and durability than today’s weekly injections.
The obesity market is rapidly becoming much bigger than “who has the best GLP-1.”
I’m hopeful for a future where we get to the root causes of metabolic dysfunction and disease. This feels like Lilly taking a step in that direction.
Compounded VS Branded GLP-1: Do People Know the Difference? xitter.cf/i/broadcasts/1dKrPrjvw…
$GUTS has always been very exciting to me as someone living with diabetes and obesity. I’m still extremely excited about what they are doing at @FractylHealth.
It’s not without serious questions. The 3 main questions I have:
1. Can they effectively train administering physicians on the technique and importance of the length of the ablation to the duodenum, given its effectiveness correlative. (Especially given that they’ve struggled to do that and tightly controlled clinical trials.)
2. Will the durability hold over time? Is it truly a “one and done”?
3. How much will it cost?
@JCanNuSH also raised another great question about PBMs using it to deny future coverage of AOM’s….
The GLP-1 “Off-Ramp” Just Got Its Strongest Evidence Yet xitter.cf/i/broadcasts/1dGYlaywV…
